Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice
about
The PDE1/5 Inhibitor SCH-51866 Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington's DiseaseMouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.Amitriptyline improves motor function via enhanced neurotrophin signaling and mitochondrial functions in the murine N171-82Q Huntington disease model.A small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6/2 and BACHD mice.Pharmacological enhancement of memory or cognition in normal subjectsImplantation of undifferentiated and pre-differentiated human neural stem cells in the R6/2 transgenic mouse model of Huntington's diseaseTherapeutic approaches to preventing cell death in Huntington diseaseTherapeutic advances in Huntington's Disease.AMPA receptor potentiators: from drug design to cognitive enhancementConditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction.Protein misfolding detected early in pathogenesis of transgenic mouse model of Huntington disease using amyloid seeding assay.The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease miceDysfunction of the ubiquitin ligase Ube3a may be associated with synaptic pathophysiology in a mouse model of Huntington diseaseChronic Ampakine Treatments Stimulate Dendritic Growth and Promote Learning in Middle-Aged RatsImbalance of p75(NTR)/TrkB protein expression in Huntington's disease: implication for neuroprotective therapies.Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.An Intrabody Drug (rAAV6-INT41) Reduces the Binding of N-Terminal Huntingtin Fragment(s) to DNA to Basal Levels in PC12 Cells and Delays Cognitive Loss in the R6/2 Animal ModelA small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration.Cognitive dysfunction in Huntington's disease: mechanisms and therapeutic strategies beyond BDNF.Pharmacological characterisation of S 47445, a novel positive allosteric modulator of AMPA receptorsAmpakines promote spine actin polymerization, long-term potentiation, and learning in a mouse model of Angelman syndrome.Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets.Mechanism based approaches for rescuing and enhancing cognition.Modulating Neurotrophin Receptor Signaling as a Therapeutic Strategy for Huntington's Disease.Pharmacological Modulation of AMPAR Rescues Intellectual Disability-Like Phenotype in Tm4sf2-/y Mice.
P2860
Q21092845-F6C54F7C-9E23-4CF4-8FE4-74F212DCCCF6Q27005950-F591C91B-34FC-4988-BAE3-9E54780C9E8DQ27314860-3EB9969E-B5CF-4172-9E43-CECDDE62A27DQ33640604-33BD5DCC-568F-4F09-8884-5EEDA3E2D2A2Q33659760-CF176D04-C41F-4D27-B337-CFBB76D10520Q34372919-EFA4D7E9-5140-4E59-B4DC-FD22E53B3799Q34411338-C2ADA67D-B9B7-4C82-AA54-B9C57E04F71AQ34487604-4DC720DC-CD55-47B5-98F1-CE8604A65692Q35054673-80660DDD-92DC-4BC9-93F8-8B6D72F5AC67Q35487248-CCFEF74E-445D-4EC1-B524-8CDEB7572F80Q35880053-A07C508F-0D04-4BBA-88AD-3B58B4450C86Q36037085-2C207BFC-A994-4F1A-8BBA-6196DA22E758Q36216036-C2584312-0694-479C-A939-CA0DB7D91078Q36534364-EB08A64B-5919-4031-8428-6362CF563FDAQ36809523-C225F513-A355-4116-8C2D-A6CC97EC8E49Q36813115-18E895C9-29A7-49EC-8D38-016810B7721AQ37198517-CBC72FDB-863D-4B48-BB5C-271A53F6A56CQ37345118-49EEF338-932E-4BDF-B136-3BF35087116DQ37384081-AD8AEBB6-E462-4A3D-A7D6-EB72C93E84CFQ38928777-03BE3F3F-BB77-4FB3-B2EF-7A08384B42CDQ41491434-AB0AC95B-EAD7-4DB0-A831-08EA0EFE66D7Q41890887-316EAAE1-26B2-44AC-9A8C-E6AEC394A138Q42097305-FB0EBFBC-B681-4BA7-B23D-1C159A1DF2C4Q42555375-DBF3496B-0AA7-46C1-A8A5-7B163CF45C06Q47280331-D6DDE921-85E1-4F71-82C9-5C2E97705840Q47610094-7A37BBB3-901A-43D4-8DA9-1FA070CEE414
P2860
Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Brief ampakine treatments slow ...... isease phenotypes in R6/2 mice
@ast
Brief ampakine treatments slow ...... isease phenotypes in R6/2 mice
@en
Brief ampakine treatments slow ...... isease phenotypes in R6/2 mice
@nl
type
label
Brief ampakine treatments slow ...... isease phenotypes in R6/2 mice
@ast
Brief ampakine treatments slow ...... isease phenotypes in R6/2 mice
@en
Brief ampakine treatments slow ...... isease phenotypes in R6/2 mice
@nl
prefLabel
Brief ampakine treatments slow ...... isease phenotypes in R6/2 mice
@ast
Brief ampakine treatments slow ...... isease phenotypes in R6/2 mice
@en
Brief ampakine treatments slow ...... isease phenotypes in R6/2 mice
@nl
P2093
P2860
P1476
Brief ampakine treatments slow ...... isease phenotypes in R6/2 mice
@en
P2093
Christine M Gall
Danielle A Simmons
Gary Lynch
Julie C Lauterborn
Rishi A Mehta
P2860
P304
P356
10.1016/J.NBD.2010.10.015
P577
2010-10-23T00:00:00Z